Rapid Therapeutic Science Stock Performance
| RTSL Stock | USD 0 0.00 0.00% |
On a scale of 0 to 100, Rapid Therapeutic holds a performance score of 4. The company holds a Beta of 6.01, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Rapid Therapeutic will likely underperform. Please check Rapid Therapeutic's treynor ratio and day median price , to make a quick decision on whether Rapid Therapeutic's historical price patterns will revert.
Risk-Adjusted Performance
4 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Rapid Therapeutic Science are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. Despite quite conflicting basic indicators, Rapid Therapeutic disclosed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 499.1 K | |
| Total Cashflows From Investing Activities | -292.5 K |
Rapid |
Rapid Therapeutic Relative Risk vs. Return Landscape
If you would invest 0.20 in Rapid Therapeutic Science on October 11, 2024 and sell it today you would earn a total of 0.00 from holding Rapid Therapeutic Science or generate 0.0% return on investment over 90 days. Rapid Therapeutic Science is currently generating 0.8197% in daily expected returns and assumes 14.4101% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Rapid, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Rapid Therapeutic Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Rapid Therapeutic's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Rapid Therapeutic Science, and traders can use it to determine the average amount a Rapid Therapeutic's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0569
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | RTSL | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 14.41 actual daily | 96 96% of assets are less volatile |
Expected Return
| 0.82 actual daily | 16 84% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 4 96% of assets perform better |
Based on monthly moving average Rapid Therapeutic is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Rapid Therapeutic by adding it to a well-diversified portfolio.
Rapid Therapeutic Fundamentals Growth
Rapid Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Rapid Therapeutic, and Rapid Therapeutic fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Rapid Pink Sheet performance.
| Return On Asset | -0.55 | |||
| Current Valuation | 13.08 M | |||
| Shares Outstanding | 7.75 M | |||
| Price To Book | 136.70 X | |||
| Price To Sales | 193,667 X | |||
| Revenue | 534 | |||
| EBITDA | (1.48 M) | |||
| Cash And Equivalents | 112.16 K | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 150 K | |||
| Debt To Equity | 1.13 % | |||
| Book Value Per Share | (0.40) X | |||
| Cash Flow From Operations | (2.21 M) | |||
| Earnings Per Share | (0.51) X | |||
| Total Asset | 2.2 M | |||
About Rapid Therapeutic Performance
By examining Rapid Therapeutic's fundamental ratios, stakeholders can obtain critical insights into Rapid Therapeutic's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Rapid Therapeutic is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Rapid Therapeutic Science Laboratories, Inc. operates as a biotech company. Rapid Therapeutic Science Laboratories, Inc. was a former subsidiary of Texas Mdi, Inc. Rapid Therapeutic operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 8 people.Things to note about Rapid Therapeutic Science performance evaluation
Checking the ongoing alerts about Rapid Therapeutic for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Rapid Therapeutic Science help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Rapid Therapeutic is way too risky over 90 days horizon | |
| Rapid Therapeutic has some characteristics of a very speculative penny stock | |
| Rapid Therapeutic appears to be risky and price may revert if volatility continues | |
| Rapid Therapeutic Science currently holds 150 K in liabilities with Debt to Equity (D/E) ratio of 1.13, which is about average as compared to similar companies. Rapid Therapeutic Science has a current ratio of 0.07, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Rapid Therapeutic until it has trouble settling it off, either with new capital or with free cash flow. So, Rapid Therapeutic's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Rapid Therapeutic Science sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Rapid to invest in growth at high rates of return. When we think about Rapid Therapeutic's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 534. Net Loss for the year was (2.87 M) with profit before overhead, payroll, taxes, and interest of 334. | |
| Rapid Therapeutic Science currently holds about 112.16 K in cash with (2.21 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 66.0% of Rapid Therapeutic outstanding shares are owned by corporate insiders |
- Analyzing Rapid Therapeutic's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Rapid Therapeutic's stock is overvalued or undervalued compared to its peers.
- Examining Rapid Therapeutic's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Rapid Therapeutic's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Rapid Therapeutic's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Rapid Therapeutic's pink sheet. These opinions can provide insight into Rapid Therapeutic's potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Rapid Pink Sheet
Rapid Therapeutic financial ratios help investors to determine whether Rapid Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Rapid with respect to the benefits of owning Rapid Therapeutic security.